|
|
| XEOMIN |
Go the au natural way!
|
First there was Botox, then there was
Dysport, and now there is Xeomin. Xeomin is the newest
and most recently approved form of inject-able botulinum
to help treat those pesky wrinkles. Originally approved
to treat cervical dystonia and blepharospams, Xeomin
treatments are now on the rise and already have been
used by more than 84,000 people in 20 different
countries. It was recently approved by the Food and Drug
Administration (FDA) to treat severe frown lines or 11’s
between the eyebrows. Similar to other botoxins, Xeomin
paralyzes the wrinkles by blocking the signals from the
nerve to the muscle. Allowing you appear less angry, and
to appear to be happy and wrinkle free!
Botox, Dysport, and now Xeomin are the most common form
of the botulinum toxin type A, and although they are
similar they also have their differences. Merz
Pharmaceuticals was able to develop a manufacturing
technique to produce Xeomin au natural (which means that
unlike Botox and Dysport there are no additives). This
is especially important because it is believed that this
special production process without additives may
minimize the patient’s possibility of developing
antibodies to Xeomin. Hence, Xeomin may work in patients
where Botox and Dysport fail to achieve their desired
results.
Perhaps this is Xeomin’s greatest advantage and should
definitely be considered by any patient whose Botox or
Dysport treatment has failed in the past.
Why not give Xeomin a try? Call us today at 727-522-3223
to arrange for consultation to get started on this
exciting new treatment! |
| |
|
|
The Center for Cosmetic Facial & Eye Plastic Surgery
Lawrence G. Kass, M.D.

|
St.
Petersburg (Main) Office
6025 4th Street North
St. Petersburg, Florida 33703
Phone: (727)
522-3223 (FACE) |
Clearwater Office
1811 North Belcher Road
Clearwater, Florida 33765
Phone: (727) 725-4612 |
All Rights Reserved.
Last Updated
May 18, 2012 | Sitemap |
Privacy Policy |
Terms of Use |
Links | Web Services by
Ron Castle Webs
Content Copyright © 2011-2012 All
Rights Reserved.
|